Population pharmacokinetics of peramivir in healthy volunteers and influenza patients.
Peramivir is an intravenous anti-influenza agent that inhibits viral growth by selectively inhibiting neuraminidase in human influenza A and B viruses. To characterize its pharmacokinetics, a population pharmacokinetic analysis of peramivir was performed using 3,199 plasma concentration data samples from 332 subjects in six clinical studies in Japan and the United States, including studies with renal impairment subjects, elderly subjects, and influenza patients. A three-compartment model well described the plasma concentration data for peramivir, and creatinine clearance was found to be the most important factor influencing clearance. Age and body weight were also found to be covariates for clearance and the volume of distribution, respectively. No difference in pharmacokinetics was found between genders or between Japanese and U.S.


METHODS
Small differences in pharmacokinetics were observed between uninfected subjects and influenza patients (clearance was 18% higher and the volume of distribution was 6% lower in influenza patients). Monte Carlo simulations indicated that single adjusted doses of 1/3- and 1/6-fold for patients with moderate and severe renal impairment, respectively, would give areas under the curve comparable to those for patients with normal renal function. The population pharmacokinetic model developed for peramivir should be useful for understanding its pharmacokinetic characteristics and for dose adjustment on the basis of renal function.
Clinical Pharmacology & Pharmacokinetics, Shionogi & Co., Ltd., Osaka, Japan.
Yumiko
Y
Matsuo
Clinical Pharmacology & Pharmacokinetics, Shionogi & Co., Ltd., Osaka, Japan.
Toru
T
Ishibashi
Clinical Pharmacology, BioCryst Pharmaceuticals, Inc., Durham, North Carolina, USA.
Alan S
AS
Hollister
Clinical Pharmacology & Pharmacokinetics, Shionogi & Co., Ltd., Osaka, Japan toshihiro.wajima@shionogi.co.jp.
Toshihiro
T
Wajima
D000146:Acids, Carbocyclic; D003517:Cyclopentanes / Q000097:blood* / Q000493:pharmacokinetics*; D006146:Guanidines / Q000097:blood* / Q000493:pharmacokinetics*; D064368:Healthy Volunteers; D006801:Humans; D007251:Influenza, Human / Q000097:blood*; D007564:Japan; D008962:Models, Theoretical; D009010:Monte Carlo Method; D014481:United States
D000146:Acids, Carbocyclic; D003517:Cyclopentanes; D006146:Guanidines; C414210:peramivir